Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange
Reverse Takeover

Share on Stocktwits


A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14.

Shares of PreveCeutical Medical Inc. are expected to begin trading on the Canadian Securities Exchange on July 14 under the symbol PREV. The company, named after its focus on preventative nutraceuticals, has a pipeline that includes a cannabidiol-infused soluble gel delivery system and a dual-gene therapy targeting obesity and diabetics.

In April, PreveCeutical formed a partnership with UniQuest Pty Limited at Queensland University in Australia. According to the company, UniQuest will conduct a research program "for the extraction, formulation and ex vivo evaluation of cannabinoids (CBDs) for local/direct nose-to-brain delivery via Sol-Gels. UniQuest is the main commercialisation company for The University of Queensland."

"Due to increasing evidence of the clinical benefits presented by CBDs, and recent legalisation of 'medical marijuana' across a number of jurisdictions, PMI is seeking development and evaluation of translatable formulations for central nervous system (CNS) delivery of CBDs, for which, soluble gels (sol-gels) present an ideal platform for achieving this aim, being in-solution upon administration, and rapidly gelling upon contact with mucosal tissue, paving the way for safer, reliable drug delivery for agents, such as CBDs that are rapidly metabolised, or that would benefit from direct nose-to-brain CNS delivery to provide clinical benefit," the company noted.

PreveCeutical CEO Stephen Van Deventer, in an interview with CFN Media Group, noted that "Through our research and development program with UniQuest, we are developing what we believe will be the first FDA approved, CBD-based nose to brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders."

"We believe we will have our delivery platform fully tested, approved and ready for market deployment with licensed medical marijuana company partners in approximately 18 months," Van Deventer stated.

PreveCeutical is also working with UniQuest on a dual-gene therapy for obesity and diabetes. Van Deventer noted that "PreveCeutical's plan to address this disease involves a broader, longer term program of research and development with the aim of developing a 'curative' gene therapy approach. . .with this program we aim to target the root cause of this disease using siRNA therapeutics to identify the over-expression of that key gene implicated in both diabetes and obesity."

"With the assessment of safety and efficacy in appropriate preclinical models of diabetes, we could pave the way not only to cure this disease but perhaps, in the future, prevent it all together," Van Deventer noted.

"Our goal is to have at least 3 new drugs either on the market or filed for FDA approval approximately by 2021. Our criteria are that all our development projects have the potential to generate more than $1 billion in sales each year," concluded Van Deventer.

Editor's note: An earlier version of this article stated trading should begin June 12. It has been pushed back.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new interviews and articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe